FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and pharmaceutics. Object 1 is the use of an anti-PD-1 antibody or an antigen-binding fragment thereof, either alone or in a combination with an additional anti-cancer agent selected from one or more CDK4/6 inhibitors and an FGF/FGFR inhibitor, for treating oesophageal squamous cell carcinoma, having no 11q13 gene amplification. Object 2 is the use of a reagent for detecting amplification of genes of chromosomal region 11q13 for predicting the therapeutic effect of the anti-PD-1 antibody or its antigen-binding fragment in a patient with squamous cell carcinoma of the oesophagus.
EFFECT: determining which patients with oesophageal squamous cell carcinoma can be effectively treated with an anti-PD-1 antibody.
20 cl, 7 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODY IN HETERODIMERIC FORM, SIMILAR IN STRUCTURE TO NATURAL ANTIBODY, AND PRODUCTION THEREOF | 2022 |
|
RU2825838C1 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
